VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 76 filers reported holding VAXCYTE INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,395,088 | -6.0% | 86,212 | -7.9% | 0.00% | -20.0% |
| Q2 2023 | $4,677,131 | +156.4% | 93,655 | +92.4% | 0.01% | +150.0% |
| Q1 2023 | $1,824,189 | -11.5% | 48,671 | +13.2% | 0.00% | 0.0% |
| Q4 2022 | $2,062,090 | +192.1% | 43,005 | +46.1% | 0.00% | +100.0% |
| Q3 2022 | $706,000 | +35.8% | 29,440 | +23.2% | 0.00% | 0.0% |
| Q2 2022 | $520,000 | +28.4% | 23,897 | +42.8% | 0.00% | – |
| Q1 2022 | $405,000 | -0.2% | 16,731 | -2.1% | 0.00% | – |
| Q4 2021 | $406,000 | +20.5% | 17,090 | +29.2% | 0.00% | – |
| Q3 2021 | $337,000 | +32.7% | 13,226 | +16.9% | 0.00% | – |
| Q2 2021 | $254,000 | -1.2% | 11,310 | -13.3% | 0.00% | – |
| Q1 2021 | $257,000 | -71.3% | 13,042 | -61.3% | 0.00% | – |
| Q4 2020 | $895,000 | – | 33,736 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,457,300 | $54,619,604 | 23.40% |
| Pivotal bioVenture Partners Investment Advisor LLC | 693,039 | $25,975,102 | 10.70% |
| RA Capital Management | 7,291,254 | $273,276,200 | 6.19% |
| Kynam Capital Management, LP | 1,216,784 | $45,605,064 | 5.89% |
| GREAT POINT PARTNERS LLC | 659,211 | $24,707,228 | 4.85% |
| Frazier Life Sciences Management, L.P. | 1,397,405 | $52,374,739 | 3.79% |
| ACUTA CAPITAL PARTNERS, LLC | 120,500 | $4,516,340 | 3.33% |
| Ghost Tree Capital, LLC | 225,000 | $8,433,000 | 2.49% |
| Carlyle Group Inc. | 1,923,158 | $72,079,962 | 2.15% |
| Opaleye Management Inc. | 177,000 | $6,633,960 | 1.99% |